Clinical trial / 2010
A proprietary probiotic formula dose-dependently reduced the incidence of antibiotic-associated and Clostridium difficile-associated diarrhea in adult inpatients.
In a dose-ranging study, 255 adult inpatients starting antibiotics were randomized to two probiotic capsules daily (Pro-2, 100 billion c.f.u.), one probiotic plus one placebo capsule daily (Pro-1, 50 billion c.f.u.), or two placebo capsules daily. AAD incidence was 15.5% in Pro-2, 28.2% in Pro-1, and 44.1% in the placebo group; in those who developed AAD, symptom duration was 2.8 days (Pro-2), 4.1 days (Pro-1), and 6.4 days (placebo). CDAD incidence was also reduced: 1.2% in Pro-2, 9.4% in Pro-1, and 23.8% in placebo. Gastrointestinal symptoms were less frequent in the probiotic groups compared to placebo and lower in Pro-2 than in Pro-1.
- Study type
- Randomized, double-blind, placebo-controlled dose-ranging trial
- Who was studied
- 255 adult inpatients receiving antibiotics
- What was measured
- Incidence of antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD), symptom duration, and gastrointestinal symptoms
THE PAPER
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Am J Gastroenterol, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.